BioTelemetry (BEAT) Tops Q2 EPS by 3c

BioTelemetry (NASDAQ: BEAT) reported Q2 EPS of $0.12, $0.03 better than the analyst estimate of $0.09. Revenue for the quarter came in at $44.8 million versus the consensus estimate of $45.75 million.

For earnings history and earnings-related data on BioTelemetry (BEAT) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• William Blair Upgrades Backblaze Inc (BLZE) to Market Perform
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity